ArticleJournal of medical microbiology2022
Article in Journal of medical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- The redefined identity ofJournal of bacteriology · 2026Review
- Sputum Microbiome Based on the Etiology and Severity of Nontuberculous Mycobacterial Pulmonary Disease.Journal of clinical medicine · 2025Article
- Diagnostic value of metagenomic next-generation sequencing in the etiological diagnosis of lower respiratory tract infection.Scientific reports · 2025Article
- Comparison of the sputum microbiome between patients with stable nontuberculous mycobacterial pulmonary disease and patients requiring treatment.BMC microbiology · 2024Article
- The presence of cystic fibrosis-related diabetes modifies the sputum microbiome in cystic fibrosis disease.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Comparison of single-visit versus multiple-visit root canal therapy for chronic anterior apical periodontitis.American journal of translational research · 2024Article
- Valid and accepted novel bacterial taxa derived from human clinical specimens and taxonomic revisions published in 2022.Journal of clinical microbiology · 2023Review
- Glucose-lowering effects of a synbiotic combination containing Pediococcus acidilactici in C. elegans and mice.Diabetologia · 2023Article
- Identification of a growth factor required for culturing specific fastidious oral bacteria.Journal of oral microbiology · 2023Article
- Overcoming Antibiotic Resistance with Novel Paradigms of Antibiotic Selection.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Although anaerobic bacteria exist in abundance in cystic fibrosis (CF) airways, their role in disease progression is poorly understood. We hypothesized that the presence and relative abundance of the most prevalent, live, anaerobic bacteria in sputum of adults with CF were associated with adverse clinical outcomes. This is the first study to prospectively investigate viable anaerobic bacteria present in the sputum microbiota and their relationship with long-term outcomes in adults with CF. We performed 16S rRNA analysis using a viability quantitative PCR technique on sputum samples obtained from a prospective cohort of 70 adults with CF and collected clinical data over an 8 year follow-up period. We examined the associations of the ten most abundant obligate anaerobic bacteria present in the sputum with annual rate of FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.